at the crossroads of evidence-based nsclc care
Published 7 years ago • 254 plays • Length 1:40:14Download video MP4
Download video MP3
Similar videos
-
1:43:59
nsclc forum: bringing the patient to the foreground of evidence-based lung cancer care
-
1:44:45
gaining an advantage over nsclc: how to achieve the greatest benefit with immunotherapy
-
51:59
facilitating progress in the treatment of sclc
-
1:08:00
has immunotherapy brought us to an inflection point in the management of stage i-iii nsclc?
-
1:20
the crossroads of targeted therapy and immunotherapy in lung cancer
-
3:54
lung cancer warning signs ii lung cancer symptoms
-
47:57
lung cancer new treatment 2023
-
31:55
മാരക രോഗങ്ങൾക്ക് വിട - ന്യൂട്രീഷൻ ചികിത്സയിലൂടെ അത്ഭുത രോഗശാന്തി exclusive interview dr.a.sreekumar
-
1:07:31
precision decisions in genomic testing and targeted treatment of nsclc
-
1:01:42
drs. shu & stiles discuss #nsclc at #aats2023 - https://bit.ly/3vg1zva
-
57:46
virtual panel discussion: breath of hope on lung cancer awareness
-
36:55
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
1:06:23
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
58:27
addressing key targets in advanced nsclc: her2-, her3-, and trop2-targeted therapies
-
1:13:59
perfecting precision in nsclc practice: are you optimally integrating biomarker-driven therapy?
-
59:37
refining biomarker testing and targeted treatment of nsclc with egfr mutations
-
48:02
transforming care and outcomes with immunotherapy in stage i-iii resectable nsclc
-
1:11:21
maximizing the potential of immunotherapy in unresectable stage iii nsclc
-
1:24:26
assessing the impact of therapeutic advances in sclc
-
37:43
selective inhibition of oncogenic transcription and other approaches in the treatment of sclc